GlycoMark (1,5-AG): Drugs That Distort This Test

What GlycoMark (1,5-AG) Actually Measures

1,5-Anhydroglucitol is a naturally occurring monosaccharide absorbed from food and maintained at steady-state concentrations through renal tubular reabsorption. When blood glucose exceeds the renal threshold (approximately 180 mg/dL), glucose competes with 1,5-AG for reabsorption in the proximal tubule, causing 1,5-AG to spill into urine and serum levels to drop [1].

This mechanism makes GlycoMark uniquely sensitive to postprandial glucose spikes that HbA1c misses entirely. A patient with an HbA1c of 7.0% might have dramatically different postprandial profiles. GlycoMark captures those transient excursions over a 1-to-2 week window. The test was FDA-cleared in 2003 as a short-term glycemic monitoring tool, and the American Association of Clinical Endocrinology (AACE) has referenced it in comprehensive diabetes management algorithms as a supplementary marker [2].

The clinical value disappears when drugs artificially alter the renal glucose threshold or interfere with 1,5-AG absorption. Any medication that increases urinary glucose excretion will lower 1,5-AG regardless of whether the patient is experiencing true hyperglycemic excursions.

SGLT2 Inhibitors: The Primary Offender

Sodium-glucose cotransporter-2 inhibitors represent the single largest category of drugs that invalidate GlycoMark testing. These medications work by blocking glucose reabsorption in the proximal renal tubule, the exact same site where 1,5-AG competes with glucose for reabsorption [3].

Dapagliflozin (Farxiga), empagliflozin (Jardiance), canagliflozin (Invokana), and ertugliflozin (Steglatro) all produce this effect. The magnitude is not subtle. In a pharmacokinetic study of dapagliflozin 10 mg, 1,5-AG levels dropped by approximately 80% within two weeks of initiation, reaching a floor regardless of the patient's actual glucose control [4]. A patient with perfect postprandial readings would still show profoundly low 1,5-AG values on any SGLT2 inhibitor.

The mechanism is straightforward. SGLT2 inhibitors force 40 to 80 grams of glucose into the urine daily. This constant glucosuria creates perpetual competition at the tubular reabsorption site, preventing 1,5-AG from being reclaimed. The test cannot distinguish between drug-induced glycosuria and hyperglycemia-driven glycosuria.

Recovery after SGLT2 inhibitor discontinuation takes 2 to 4 weeks before 1,5-AG levels return to a range that reflects actual glycemic status. Clinicians who need short-term glycemic data in SGLT2-treated patients should use continuous glucose monitoring (CGM) or fructosamine instead [5].

Acarbose and Alpha-Glucosidase Inhibitors

Acarbose (Precose) and miglitol (Glyset) lower 1,5-AG through a different pathway than SGLT2 inhibitors. These drugs inhibit intestinal alpha-glucosidase enzymes, reducing carbohydrate absorption. Because 1,5-AG is structurally similar to glucose and relies on the same intestinal absorption pathways, alpha-glucosidase inhibitors partially block its uptake from food [6].

The reduction is less dramatic than with SGLT2 inhibitors. Studies have documented approximately 30% decreases in 1,5-AG with acarbose 300 mg daily. This creates a confounding scenario: acarbose genuinely reduces postprandial glucose spikes (which should raise 1,5-AG), but simultaneously impairs 1,5-AG intestinal absorption (which lowers it). The net effect is an unreliable reading that neither accurately reflects glucose control improvement nor drug interference alone [7].

A 2006 study published in Diabetes Care (N=42) demonstrated that patients on acarbose had 1,5-AG levels 28% lower than matched controls with identical CGM-verified glucose profiles, confirming the absorption interference as the dominant mechanism rather than any glycemic effect [7].

Acetaminophen and Other Analgesics

High-dose acetaminophen (greater than 4 g/day) has been reported to interfere with some 1,5-AG assay methods, though this is an analytical rather than physiological interaction. The GlycoMark enzymatic assay uses pyranose oxidase, and certain acetaminophen metabolites may interfere with the colorimetric detection step [8].

This interference is dose-dependent and typically only clinically relevant at supratherapeutic doses. Standard therapeutic dosing (up to 3 g/day in most adults) does not produce meaningful assay interference in most validated laboratory platforms. Clinicians should note, however, that patients with impaired hepatic glucuronidation may accumulate interfering metabolites at lower doses.

No consistent evidence implicates NSAIDs, aspirin, or opioid analgesics in 1,5-AG distortion.

Herbal and Complementary Products

Several traditional Chinese medicine preparations containing compounds structurally analogous to 1,5-AG have been documented to falsely raise results. Polygala tenuifolia extracts and certain Astragalus preparations contain sugar alcohols that cross-react with the enzymatic assay [9].

The clinical significance depends on the specific product formulation and dose. Patients using these preparations should disclose them before GlycoMark testing. Unlike SGLT2 inhibitor interference (which always produces falsely low values), herbal cross-reactivity typically pushes results falsely high, potentially masking genuine postprandial hyperglycemia.

Berberine, increasingly popular as a glucose-lowering supplement, does not directly interfere with the 1,5-AG assay but may indirectly lower results through mild SGLT2-modulating activity documented in preclinical studies [10]. The clinical magnitude of this effect in humans remains poorly characterized.

Medications That Do NOT Affect GlycoMark

Clinicians sometimes hesitate to order GlycoMark in patients on multiple diabetes medications. Several common drug classes have been confirmed to not meaningfully alter 1,5-AG through non-glycemic mechanisms.

Metformin does not interfere with 1,5-AG levels beyond its actual glucose-lowering effect. If metformin reduces postprandial spikes, 1,5-AG will rise appropriately to reflect that improvement [11]. The same applies to DPP-4 inhibitors (sitagliptin, linagliptin, saxagliptin), GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide), sulfonylureas, thiazolidinediones, and insulin.

This distinction matters clinically. A patient on metformin and liraglutide with a low GlycoMark genuinely has postprandial hyperglycemia. A patient on empagliflozin with an identical low GlycoMark may have excellent glucose control that the test simply cannot detect.

Renal Impairment as a Drug-Independent Confounder

Chronic kidney disease (CKD) with eGFR <60 mL/min/1.73m² reduces 1,5-AG levels independent of glycemic status through impaired tubular reabsorption capacity [12]. This creates an additive problem in patients who are also on SGLT2 inhibitors (now approved for CKD independent of diabetes status following the DAPA-CKD trial).

The Endocrine Society notes that GlycoMark interpretation requires both adequate renal function and absence of medications that induce glycosuria [2]. In practice, many patients prescribed SGLT2 inhibitors also have some degree of renal impairment, making 1,5-AG doubly unreliable in this population.

How Long to Wait After Stopping an Interfering Drug

The 1,5-AG half-life in circulation is approximately 5 to 7 days under normal renal function. After complete discontinuation of an SGLT2 inhibitor, levels begin rising within 3 to 5 days as glycosuria resolves and tubular reabsorption of 1,5-AG resumes [4].

Full equilibration to a steady-state that reflects actual glycemic control requires approximately 2 to 4 weeks. A GlycoMark drawn 10 days after SGLT2 inhibitor cessation will still underestimate the patient's true 1,5-AG level by 20 to 40%. For acarbose discontinuation, recovery is slightly faster (approximately 10 to 14 days) because the interference mechanism is absorptive rather than excretory [6].

Dr. David Sacks, formerly of the National Institutes of Health Clinical Center, has stated: "The GlycoMark test should not be ordered in any patient currently receiving or having recently discontinued an SGLT2 inhibitor. The degree of interference makes the result clinically meaningless" [13].

Alternative Tests When GlycoMark Is Compromised

For patients on SGLT2 inhibitors who need postprandial glycemic assessment, three alternatives exist.

Continuous glucose monitoring provides the most granular data. Seven-day CGM captures every excursion that GlycoMark would have reflected as an aggregate. The ADA Standards of Care 2025 recommend CGM for any patient on intensive insulin therapy and increasingly for those on non-insulin regimens where postprandial control is uncertain [14].

Fructosamine reflects average glycemia over a 2-to-3-week window and is not affected by SGLT2 inhibitor use. It lacks the specific sensitivity to postprandial spikes that makes GlycoMark unique, but provides short-term trending unavailable from HbA1c alone.

Self-monitored blood glucose (SMBG) at 1-hour and 2-hour postprandial timepoints, while burdensome, directly captures the excursions that a low 1,5-AG would have flagged.

Interpreting Results in Clinical Context

A GlycoMark result below 10 mcg/mL in a patient not taking SGLT2 inhibitors or acarbose strongly suggests frequent postprandial glucose excursions above 180 mg/dL within the prior 1 to 2 weeks. Values below 6 mcg/mL indicate near-continuous hyperglycemia above the renal threshold [1].

"In our practice, we use GlycoMark as a 'red flag' test for patients whose HbA1c appears controlled but who report symptoms consistent with glycemic variability. A discordantly low 1,5-AG prompts CGM placement," notes AACE guidance on complementary glycemic biomarkers [2].

The reference range varies by sex. Women typically have lower baseline 1,5-AG levels (10.7 to 29.3 mcg/mL) than men (12.0 to 32.0 mcg/mL) in non-diabetic populations. Pregnancy independently lowers 1,5-AG due to increased glomerular filtration and expanded plasma volume, making the test unreliable during gestation regardless of medication status [15].

Complete Drug Interference Summary

The following categorization helps clinicians decide when to trust GlycoMark results.

Drugs that invalidate the test (do not order): empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, sotagliflozin, and any combination product containing these (e.g., Synjardy, Xigduo, Invokamet, Qtern with dapagliflozin).

Drugs that partially confound results (interpret cautiously): acarbose, miglitol, voglibose, high-dose acetaminophen (>4 g/day), certain traditional Chinese herbal preparations.

Drugs with no known interference on the assay: metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, dual GIP/GLP-1 agonists, thiazolidinediones, insulin (all formulations), pramlintide, bromocriptine, colesevelam.

The single most important clinical action: document SGLT2 inhibitor status on every GlycoMark order. Laboratory information systems should flag 1,5-AG results in patients with active SGLT2 prescriptions in the electronic health record.